Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05786443 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
A Phase 2 study of End Stage Renal Disease, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT05786443 is a Phase 2 study of End Stage Renal Disease that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 60 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05786443, a Phase 2 study of End Stage Renal Disease, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
A 12-week, phase II, randomized, double-blind, placebo-controlled, multi-center study to assess the safety, tolerability, and preliminary efficacy of empagliflozin versus placebo among patients initiating hemodialysis (n=60) for the treatment of end-stage kidney disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Empagliflozin 10 MG
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05786443
The ClinicalTrials.gov registry entry for NCT05786443 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (93% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05786443 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT05786443 about?
NCT05786443 is a clinical study titled "Safety and Efficacy of Empagliflozin in Hemodialysis". A 12-week, phase II, randomized, double-blind, placebo-controlled, multi-center study to assess the safety, tolerability, and preliminary efficacy of empagliflozin versus placebo among patients initiating hemodialysis (n=60) for the treatment of end-stage kidney disease.
What is the current status of trial NCT05786443?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-01-31. Estimated completion is 2026-12-30.
What conditions does trial NCT05786443 study?
This clinical trial studies the following conditions: End Stage Renal Disease.
What interventions are being tested in trial NCT05786443?
The interventions under investigation include: Placebo (DRUG), Empagliflozin 10 MG (DRUG).
Who is sponsoring clinical trial NCT05786443?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05786443 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
RECRUITING · Phase 2
-
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
RECRUITING · Phase 2
-
Communication During Hospitalization About Resuscitation Trial
ACTIVE NOT RECRUITING · Phase 2
-
The Effects of Resistance Exercise and Protein Supplementation in Hemodialysis Patients
COMPLETED · Phase 2
-
Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis
COMPLETED · Phase 2
-
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.